---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-005782"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-08-16T23:59:59+00:00"
generated_at: "2026-06-23T23:21:37.520283+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte (PMCB) reaches cooperation deal with Iroquois; appoints five new independent directors

## Summary
- Five prior directors resigned; five new directors appointed to reconstituted 7-member board effective Aug 15, 2022.
- Iroquois, holding ~6.7% stake, gets two appointees (Schechter, Silverman); standstill until Sept 30, 2024 or later.
- New independent directors: Allen, Farb, Stover join existing directors Waggoner and Abecassis.
- New directors receive $12,500/quarter cash retainer, 334 shares, and option for 334 shares with five-year term.
- Iroquois agreed to customary standstill, including voting and ownership limits (14.9% cap) through standstill period.

## SEC filing metadata
- accession: 0001683168-22-005782
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-08-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/pharmacyte_8k-081422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-005782
- JSON: https://secwatch.observer/filing/0001683168-22-005782.json
- Plain text: https://secwatch.observer/filing/0001683168-22-005782.txt

## Key facts
- Executive change
  Farb was appointed as director at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: director
  source text: effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Dr. Matthias Löhr resigned as director at PharmaCyte Biotech, Inc..
  - Action: resigned
  - Role: director
  source text: effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Allen was appointed as director at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: director
  source text: effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Stover was appointed as director at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: director
  source text: effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Dr. Tong resigned as director at PharmaCyte Biotech, Inc..
  - Action: resigned
  - Role: director
  source text: effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Mr. Liquard resigned as director at PharmaCyte Biotech, Inc..
  - Action: resigned
  - Role: director
  source text: effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Schechter was appointed as director at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: director
  source text: effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Silverman was appointed as director at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: director
  source text: effective August 15, 2022, the Board appointed each of Messrs. Schechter, Silverman, Allen, Farb and Stover as independent members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Dr. Crabtree resigned as director at PharmaCyte Biotech, Inc..
  - Action: resigned
  - Role: director
  source text: effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm
- Executive change
  Mr. Trujillo resigned as director at PharmaCyte Biotech, Inc..
  - Action: resigned
  - Role: director
  source text: effective August 15, 2022, each of Dr. Matthias Löhr, Dr. Tong, Mr. Liquard, Dr. Crabtree, and Mr. Trujillo resigned as members of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822005782/0001683168-22-005782-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.